Cost-benefit analysis and health care evaluations

Cost-Benefit Analysis and Health Care Evaluations

Volumn , Issue , 2003, Pages 1-373

  Brent, Robert J ^a  

^a FORDHAM UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85088469898     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.4337/9781843766988     Document Type: Book

References (188)

1. Ashton, T. (1991), ‘Cost-Effectiveness of Alternative Medications in the Treatment of Duodenal Ulcer’, Scandinavian Journal of Gastroenterology, 26, 82–8.
2. Axnick, N.W., Shavell, S.M. and Witte, J.J. (1969), ‘Benefits due to Immunization against Measles’, Public Health Reports, 84, 673–80.
3. Ballard, C.L., Shoven, J.B. and Whalley, J. (1985), ‘General Equilibrium Computations of the Marginal Welfare Costs of Taxes in the United States’, American Economic Review, 75, 128–38.
4. Bayoumi, A.M. and Redelmeier, D.A. (1999), ‘Economic Methods for Measuring the Quality of Life Associated with HIV Infection’, Quality of Life Research, 8, 471–80.
5. Bleichrodt, H. and Johannesson, M. (1997), ‘Standard Gamble, Time Trade-off and Rating Scale: Experimental Results on the Ranking Properties of QALYs’, Journal of Health Economics, 16, 155–75.
6. Bombardier et al. (1982), ‘Comparisons of Three Preference Measurement Methodologies in the Evaluation of a Functional Status Index’, in Choices in Health Care, edited by Deber, D.B. and Thompson, G.G., Department of Health Administration, University of Toronto.
7. Boyle, M.H., Torrance, G.W., Sinclair, J.C. and Horwood, J.C. (1983), ‘Economic Evaluation of Neonatal Intensive Care of Very Low Birth-Weight Infants’, New England Journal of Medicine, 308, 1300–7.
8. Brent, R.J. (1979), ‘Imputing Weights Behind Past Railway Closure Decisions Within a Cost–Benefit Framework’, Applied Economics, 9, 157–70.
9. Brent, R.J. (1980), ‘Distinguishing Between Money Income and Utility Income in Cost–Benefit Analysis’, Public Finance Quarterly, 8, 131–52.
10. Brent, R.J. (1984a), ‘On the Use of Distributional Weights in Cost–Benefit Analysis: A Survey of Schools’, Public Finance Quarterly, 12, 213–30.
11. Brent, R.J. (1984b), ‘A Three Objective Social Welfare Function for Cost–Benefit Analysis’, Applied Economics, 16, 369–78.
12. Brent, R.J. (1986), ‘An Axiomatic Basis for the Three Objective Social Welfare Functions Within a Poverty Context’, Economics Letters, 20, 89–94.
13. Brent, R.J. (1991a), ‘A New Approach to Valuing a Life’, Journal of Public Economics, 44, 165–71.
14. Brent, R.J. (1991b), ‘The Numbers Effect and the Shadow Wage in Project Appraisal’, Public Finance, 46, 118–27.
15. Brent, R.J. (1992), ‘The Consumption Rate of Interest and the Numbers Effect’, Public Finance, 47, 367–77.
16. Brent, R.J. (1993), ‘Country Estimates of Social Discount Rates based on Changes in Life Expectancies’, Kyklos, 46, 399–409.
17. Brent, R.J. (1994a), ‘Shadow Prices for a Physician’s Services’, Applied Economics, 26, 669–76.
18. Brent, R.J. (1994b),‘Counting and Double-Counting in Project Appraisal’, Project Appraisal, 9, 275–81.
19. Brent, R.J. (1996), Applied Cost–Benefit Analysis, Cheltenham: Edward Elgar.
20. Brent, R.J. (1998a), Cost–Benefit Analysis for Developing Countries, Cheltenham: Edward Elgar.
21. Brent, R.J. (1998b), ‘Estimating the Effectiveness and Benefits of Alcohol Treatment Programmes for Use in Economic Evaluations’, Applied Economics, 30, 217–26.
22. Brent, R.J. (2000a), ‘An Economic Evaluation of the Privatization of Inpatient Psychiatric Services for Non-Federal General Hospitals’, Department of Economics, Fordham University.
23. Brent, R.J. (2000b), ‘The Role of Public and Private Transfers in the Cost–Benefit Analysis of Mental Health Programs’, Department of Economics, Fordham University.
24. Brent, R.J. (2002), ‘A Simple Method for Converting a Cost-Effectiveness Analysis into a Cost–Benefit Analysis with an Application to State Mental Health Expenditures’, Public Finance Review, 30, 144–60.
25. Brent, R.J. (2003), ‘The Tax Implications of Cost Shifting in Cost–Benefit Analysis in Mental Health’, Applied Economics (forthcoming).
26. Brent, R.J. and Patel, M. (1997), ‘Physician Rewards for Different Kinds of Service’, Journal of Plastic and Reconstructive Surgery, 100, 51–7.
27. Brown, G.C. (1999), ‘Vision and Quality-of-Life’, Transactions of the American Ophthalmological Society, 97, 473–511.
28. Brown, K. and Burrows, C. (1990), ‘The Sixth Stool Guaiac Test, $47 Million that Never Was’, Journal of Health Economics, 9, 429–45.
29. Browning, E.K. and Browning, J.M. (1994), Public Finance and the Price System, (4th edn), New Jersey: Prentice Hall.
30. Buchanan, J.M. and Stubblebine, C. (1962), ‘Externality’, Economica, 29, 371–84.
31. Buchanan, J.M. and Tullock, G. (1962), The Calculus of Consent, Ann Arbor: University of Michigan Press.
32. Cairns, J.A. and Van Der Pol, M.M. (1997), ‘Saving Future Lives: A Comparison of Three Discounting Models’, Health Economics, 6, 341–50.
33. Cartwright, W.S. and Solano, P. (2001), ‘The Economics of Public Health: Financing Drug Abuse Treatment Services’, National Institute on Drug Abuse and University of Delaware.
34. Chang, R.W., Pellissier, J.M. and Hazen, G.H. (1996), ‘A Cost-Effective Analysis of Total Hip Arthroplasty for Osteoarthritis of the Hip’, Journal of the American Medical Association, 275, 858–65.
35. Churchill, D.N., Torrance, G.W., Taylor, D.W., Barnes, C.C., Ludwin, D., Shimizu, A. and Smith, E.K.M. (1987), ‘Measurement of Quality of Life in End-Stage Renal Disease: The Time Trade-Off Approach’, Clinical and Investigative Medicine, 10, 14–20.
36. Clarke, R.E., Teague, G.B., Ricketts, S.K., Bush, P.W., Keller, A.M., Zubkoff, M. and Drake, R.E. (1994), ‘Measuring Resource Use in Economic Evaluations: Determining the Social Costs of Mental Illness’, The Journal of Mental Health Administration, 21, 32–41.
37. Conley, B.C. (1976), ‘The Value of Human Life in the Demand for Safety’, American Economic Review, 66, 45–55.
38. Cook, J., Richardson, J. and Street, A. (1994), ‘A Cost Utility Analysis of Treatment Options for Gallstone Disease, Methodological Issues and Results’, Health Economics, 3, 157–68.
39. Cullis, J.G. and Jones, P.G. (1986), ‘Rationing by Waiting Lists: An Implication’, American Economic Review, 74, 250–6.
40. Culyer, A.J. (1982), ‘Health Care and the Market, A British Lament’, Journal of Health Economics, 1, 299–303.
41. Dickey, B. (1995), unpublished paper, Belmont, Massachusetts: Mental Health Services Research.
42. Dolan, P. (1998), ‘The Measurement of Individual Utility and Social Welfare’, Journal of Health Economics, 17, 39–52.
43. Dolan, P. and Green, C. (1998), ‘Using the Person Trade-Off approach to Examine Differences between Individual and Social Values’, Health Economics, 7, 307–12.
44. Donaldson, C. (1990), ‘Willingness to Pay for Publicly-Provided Goods: A Possible Measure of Benefit?’, Journal of Health Economics’, 9, 103–18.
45. Doubilet, P., Weinstein, M.C. and McNeil, B.J. (1986), ‘Use and Misuse of the Term “Cost-Effective” in Medicine’, New England Journal of Medicine, 314, 253–6.
46. Dranove, D. (1995), ‘Measuring Costs’, in Sloan, F.A. (ed.), Valuing Health Care, New York: Cambridge University Press.
47. Drummond, M.F. (1981), ‘Welfare Economics and Cost–Benefit Analysis in Health Care’, Scottish Journal of Political Economy, 28, 125–45.
48. Drummond, M.F. (1990), ‘Priority Setting for AIDS and Other Health Care Programmes’, in Drummond, M.F. and Davies, L.M. (eds), AIDS: The Challenge for Economic Analysis, Birmingham: Health Services Management Centre in collaboration with the WHO.
49. Drummond, M.F., O’Brien, B., Stoddart, G.L. and Torrance, G.W. (1987), Methods for Economic Evaluation of Health Care Programmes (2nd edn), New York: Oxford University Press.
50. Drummond, M.F., Stoddart, G.L. and Torrance, G.W. (1987), Methods for Economic Evaluation of Health Care Programmes, New York: Oxford University Press.
51. Drummond, M., Torrance, G. and Mason, J. (1993), ‘Cost-Effectiveness League Tables: More Harm than Good’, Social Science and Medicine, 37, 33–40.
52. Eddy, D.M. (1991a), ‘Oregon’s Methods. Did Cost-Effectiveness Analysis Fail?’, Journal of the American Medical Association, 266, 2135–41.
53. Eddy, D.M. (1991b), ‘Oregon’s Methods. Should it be Approved?’, Journal of the American Medical Association, 266, 2439–45.
54. Elixhauser, A., Luce, B.R., Taylor, W.R. and Reblando, J. (1993), ‘Health Care CBA/ CEA, An Update on the Growth and Composition of the Literature’, Medical Care, 31, JS1–JS11.
55. Epstein, J.F. and Grfeorer, J.C. (1995), ‘Estimating Substance Abuse Treatment Need from a National Household Survey’, paper presented at the 37th International Congress on Alcohol and Drug Dependence.
56. Fingarette, H. (1988), Heavy Drinking, Berkeley: University of California Press.
57. Finkler, S.A. (1982), ‘The Distinction Between Cost and Charges’, Annals of Internal Medicine, 96, 102–9.
58. Forester, T.H., McNown, R.F. and Singell, L.D. (1984), ‘A Cost–Benefit Analysis of the 55 MPH Speed Limit’, Southern Economic Journal, 50, 631–41.
59. Frank, R.G. (1991), ‘Clozapines Cost–Benefits’ [letter], Hospital and Community Psychiatry, 42, 92.
60. French, M.T., Mauskopf, J.A., Teague, J.L. and Roland, E.J. (1996), ‘Estimating the Dollar Value of Health Outcomes from Drug Abuse Interventions’, Medical Care, 34, 890–910.
61. Fryback, D.G., Dasbach, E.J. and Klein, R. (1993), ‘The Beaver Dam Health Outcomes Study: Initial Catalog of Health-State Quality Factors’, Medical Decision Making, 13, 89–102.
62. Garbacz, C. and Thayer, M.A. (1983), ‘An Experiment in Valuing Senior Companion Program Services’, Journal of Human Resources, 18, 147–53.
63. Garber, A.M. and Phelps, C.E. (1997), ‘Economic Foundations of Cost-Effectiveness Analysis’, Journal of Health Economics, 16, 1–31.
64. Gardiner, J., Hogan, A., Holmes-Rovner, M., Rovner, D., Griffith, L. and Kupersmith, J. (1995), ‘Confidence Intervals for Cost-Effectiveness Ratios’, Medical Decision Making, 15, 254–63.
65. Gatsonis, C. (1990), ‘The Long Debate on the Sixth Stool Guaiac Test, Time to Move on to New Grounds’, Journal of Health Economics, 9, 495–7.
66. Gerard, K. and Mooney, G. (1993), ‘QALY League Tables: Handle with Care’, Health Economics, 2, 59–64.
67. Gertler, P.J., Locay, L. and Sanderson, W. (1987), ‘Are User Fees Regressive? The Welfare Implications of Health Care Financing Proposals in Peru’, Journal of Econometrics, 36, 67–88.
68. Getzen, T.E. (1997), Health Economics, Fundamentals and Flow of Funds, New York: John Wiley & Sons.
69. Ghana Health Assessment Project Team (1981), ‘A Quantitative Method of Assessing the Health Impact of Different Diseases in Less Developed Countries’, International Journal of Epidemiology, 10, 73–80.
70. Gold, M.R., Siegel, J.E., Russel, L.B. and Weinstein, M.C. (1996), Cost-Effectiveness in Health and Medicine, New York: Oxford University Press.
71. Grannemann, T.W., Brown, R.S. and Pauly, M.V. (1986), ‘Estimating Hospital Costs, A Multiple-Output Approach’, Journal of Health Economics, 5, 107–27.
72. Grob, G.N. (1994), ‘Government and Mental Health Policy: A Structural Analysis’, Millbank Quarterly, 72, 471–500.
73. Gwatkin, D.R., Guillot, M. and Heuveline, P. (1999), ‘The Burden of Disease Among the Global Poor’, The Lancet, 354, 586–9.
74. Hadley, J. (1991), ‘Theoretical and Empirical Foundations of the Resource-Based Relative Value Scale’, Ch. 5 in Frech III, H.E. (ed.), Regulating Doctors’ Fees: Competition, Benefits, and Controls under Medicare, Washington D.C.: AEI Press.
75. Hadorn, D.C. (1991), ‘Setting Health Care Priorities in Oregon. Cost-Effectiveness Analysis Meets the Rule of Reason’, Journal of the American Medical Association, 265, 2218–25.
76. Hannum, R.J. (1997), ‘Using an Expected Utility Model to Analyze the Social Costs and Benefits of Childhood Immunizations’, PhD Thesis, Department of Economics, Fordham University, New York.
77. Harper, D.R. (1979), ‘Disease Costing in a Surgical Ward’, British Medical Journal, 1, 647–9.
78. Harris, J. (1985), The Value of Life: An Introduction to Medical Ethics, London: Routledge.
79. Hellinger, F.J. (1993), ‘The Lifetime Cost of Treating a Person with HIV’, Journal of the American Medical Association, 270, 474–8.
80. Hinman, A.R. and Koplan, J.P. (1984), ‘Pertussis and Pertussis Vaccine, Reanalysis of Benefits, Risks and Costs’, Journal of the American Medical Association, 251, 3109–13.
81. Hirth, R.A., Chernew, M.E., Miller, E., Fendrick, M. and Weissert, W.G. (2000), ‘Willingness to Pay for a Quality-Adjusted Life Year: In Search for a Standard’, Medical Decision Making, 20, 332–42.
82. Hochman, H.M. and Rodgers, J.D. (1971), ‘Is Efficiency a Criterion for Judging Redistribution?’, Public Finance, 26, 76–98.
83. Horngren, C.T. (1982), Cost Accounting (5th edn), New Jersey: Prentice-Hall.
84. Hsiao, W.C., Braun, P., Kelly, N.L. and Becker, E.R. (1988), ‘Results, Potential Effects, and Implementation Issues of the Resource-Based Relative Value Scale’, Journal of the American Medical Association, 260, 2429–38.
85. Hsiao, W.C. and Dunn, D.L. (1991), ‘The Resource-Based Relative Value Scale for Pricing Physicians’ Services’, Ch. 9 in Frech III, H.E. (ed.), Regulating Doctors’ Fees, Competition, Benefits, and Controls under Medicare, Washington D.C.: AEI Press.
86. Hull, R., Hirsh, J., Sackett, D.L. and Stoddart, G. (1981), ‘Cost Effectiveness of Clinical Diagnosis, Venography, and Noninvasive Testing in Patients with Symptomatic Deep-Vein Thrombosis’, New England Journal of Medicine, 304, 1561–7.
87. Hurley, S., Kaldor, J.M., Gardiner, S., Carlin, J.B., Assuncao, R.M. and Evans, D.B. (1996), ‘Lifetime Cost of Human Immunodeficiency Virus-Related Health Care’, Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, 12, 371–8.
88. Hyder, A.A. and Morrow, R.H. (1999), ‘Steady State Assumptions in DALYs: Effect on Estimates of HIV Impact’, Journal of Epidemiology and Community Health, 53, 43–5.
89. Hyder, A.A., Rotllant, G. and Morrow, R.H. (1998), ‘Measuring the Burden of Disease: Healthy Life-Years’, American Journal of Public Health, 88, 196–202.
90. Jerrell, J.M. and Hu, T-W. (1989), ‘Cost-Effectiveness of Intensive Clinical and Case Management Compared with an Existing System of Care’, Inquiry, 26, 224–34.
91. Johannesson, M. (1999), ‘On Aggregating QALYs: a Comment on Dolan’, Journal of Health Economics, 18, 381–6.
92. Johannesson, M. and Gerdtham, U.-G. (1996), ‘A Note on the Estimation of the Equity–Efficiency Trade-off for QALYs’, Journal of Health Economics, 15, 359–68.
93. Johannesson and Johansson (1997), ‘Is the Valuation of a QALY Gained Independent of Age? Some Empirical Evidence’, Journal of Health Economics, 16, 589–99.
94. Kaplan, R.M. (1995), ‘Utility Assessment for Estimating Quality-Adjusted Life Years’, in Sloan, F.A. (ed.), Valuing Health Care, New York: Cambridge University Press.
95. Kaplan, R.M. and Bush, J.W. (1982), ‘Health Related Quality of Life Measurement for Evaluation Research and Policy Analysis’, Health Psychology, 1, 61–80.
96. Kaplan, R.M., Bush, J.W. and Berry, C.C. (1979), ‘Health Status Index’, Medical Care, 17, 501–25.
97. Keeler, E.B. and Cretin, S.B. (1983), ‘Discounting of Life-Saving and other Non-Monetary Effects’, Management Science, 29, 300–6.
98. Kind, P., Rosser, R.M. and Williams, A.H. (1982), ‘Valuations of Quality of Life: Some Psychometric Evidence’, in Jones-Lee, M.W. (ed.), The Value of Life and Safety, Amsterdam: North Holland.
99. Klarman, H.E. (1965), ‘Syphilis Control Programs’, in Dorfman, R. (ed.), Measuring Benefits of Government Investments, Washington D.C.: Brookings Institution.
100. Klarman, H.E. (1982), ‘The Road to Cost-Effectiveness Analysis’, Milbank Memorial Fund Quarterly, 60, 1–16.
101. Klarman, H.E., Francis, J. and Rosenthal, G. (1968), ‘Cost-Effectiveness Applied to the Treatment of Chronic Renal Disease’, Medical Care, 6, 48–54.
102. Klevit, H.D., Bates, A.C., Castanares, T., Kirk, E.P., Sipes-Metzler, P.R. and Wopat, R. (1991), ‘Prioritization of Health Care Services. A Progress Report by the Oregon Health Services Commission’, Archives of Internal Medicine, 151, 912–16.
103. Koplan, J.P. and Preblud, S.R. (1982), ‘A Benefit–Cost Analysis of Mumps Vaccine’, American Journal of Diseases in Children, 136, 362–4.
104. Koplan, J.P., Schoenbaum, S.C., Weinstein, M.C. and Fraser, D.W. (1979), ‘Pertussis Vaccine, An Analysis of Benefits, Risks and Costs’, New England Journal of Medicine, 301, 906–11.
105. Lasker, E.M., Meisner, M. and Siegel, C. (1997), ‘Statistical Inference for Cost-Effectiveness Ratios’, Health Economics, 6, 229–42.
106. Lightwood, J.M. and Glantz, S.A. (1997), ‘Short-Term Economic and Health Benefits of Smoking Cessation, Myocardial Infarction and Stroke’, Circulation, 96, 1089–96.
107. Lindsay, C.M. and Feigenbaum, B. (1984), ‘Rationing by Waiting Lists’, American Economic Review, 74, 405–17.
108. Linnerooth, J. (1979), ‘The Value of Life: A Review of the Models’, Economic Inquiry, 17, 52–74.
109. Llewellyn-Thomas, H. et al. (1984), ‘Describing Health States. Methodological Issues in Obtaining Values for Health States’, Medical Care, 22, 543–52.
110. Logan, A.G., Milne, B.J., Achber, R.N., Campbell, W.P. and Haynes, R.B. (1981), ‘Cost-Effectiveness of a Worksite Hypertension Treatment Program’, Hypertension, 3, 211–18.
111. Martin, S. and Smith, P. (1999), ‘Rationing by Waiting Lists: An Empirical Investigation’, Journal of Public Economics, 71, 141–64.
112. Maynard, A. (1991), ‘Developing the Health Care Market’, The Economic Journal, 101, 1277–86.
113. Mehrez, A. and Gafni, A. (1989), ‘Quality-adjusted Life Years, Utility Theory, and Healthy-years Equivalents’, Medical Decision Making, 9, 142–9.
114. Meltzer, H.Y., Cola, P., Way, L., Thompson, P.A., Bastani, B., Davies, M.A. and Switz, B. (1993), ‘Cost-Effectiveness of Clozapine in Neuroleptic-Resistant Schizophrenia’, American Journal of Psychiatry, 150, 1630–8.
115. Mishan, E.J. (1976), Cost–Benefit Analysis (3rd edn), New York: Praeger.
116. Moore, M.J. and Viscusi, W.K. (1988a), ‘The Quantity-Adjusted Value of Life’, Economic Inquiry, 26, 369–88.
117. Moore, M.J. and Viscusi, W.K. (1988b), ‘Doubling the Estimated Value of Life: Results using New Occupational Fatality Data’, Journal of Policy Analysis and Management, 7, 476–90.
118. Morrison, G.C. (1997), ‘HYE and TTO: What is the Difference?’, Journal of Health Economics, 16, 563–78.
119. Murray, C.J.L. and Acharya, A.K. (1997), ‘Understanding DALYs’, Journal of Health Economics, 16, 703–30.
120. Murray, C.J.L. and Lopez, A.D. (1996), The Global Burden of Disease. A Comprehensive Assessment of Mortality and Disability from Diseases, Injuries and Risk Factors in 1990 and Projected to 2020, Cambridge: Harvard University Press.
121. Musgrove, P. (1992), ‘Cost–Benefit Analysis of a Regional System for Vaccination Against Pneumonia, Meningitis Type B, and Typhoid Fever’, Bulletin of the Pan American Health Organization, 26, 173–91.
122. Neuhauser, D. (1990), ‘The Sixth Stool Guaiac Test, A Reply’, Journal of Health Economics, 9, 493–4.
123. Neuhauser, D. and Lewicki, M. (1975), ‘What Do We Gain from the Sixth Stool Guaiac?’, New England Journal of Medicine, 293, 226–8.
124. Nord, E. (1992), ‘Methods for Quality Adjustment of Life Years’, Social Science and Medicine, 34, 559–69.
125. Nord, E. (1993), ‘The Trade-off between Severity of Illness and Treatment Effect in Cost–Value Analysis of Health Care’, Health Policy, 24, 227–38.
126. Nord, E. (1995), ‘The Person-Trade-Off Approach to Valuing Health Care Programs’, Medical Decision Making, 15, 201–8.
127. Nord, E., Pinto, J.P., Richardson, J., Menzel, P. and Ubel, P. (1999), ‘Incorporating Societal Concerns for Fairness in Numerical Valuations of Health Programmes’, Health Economics, 8, 25–39.
128. O’Brien, B.J., Drummond, M.F., Labelle, R.J. and Willan, A. (1994), ‘In Search of Power and Significance: Issues in the Design and Analysis of Stochastic Cost-Effectiveness Studies in Health Care’, Medical Care, 32, 150–63.
129. Olsen, J.A. (1994), ‘Person vs Years: Two Ways of Eliciting Implicit Weights’, Health Economics, 3, 39–46.
130. Patrick, D.L., Bush, J.W. and Chen, M.M. (1973), ‘Methods for Measuring Well-being for a Health Status Index’, Health Services Research, 8, 228–45.
131. Pauly, M.V. (1995), ‘Valuing Health Care Benefits in Money Terms’, in Sloan, F.A. (ed.), Valuing Health Care, New York: Cambridge University Press.
132. Phelps, C.E. (1988), ‘Death and Taxes’, Journal of Health Economics, 7, 1–24.
133. Pigou, A.C. (1920), The Economics of Welfare, London: Macmillan.
134. Politi, C., Carrin, G., Evans, D., Kuzoe, F.A.S. and Cattand, P.D. (1995), ‘Cost-Effectiveness Analysis of Alternative Treatments of African Gambiense Trypanosomiasis in Uganda’, Health Economics, 4, 273–87.
135. Propper, C. (1990), ‘Contingent Valuation of Time Spent on NHS Waiting Lists’, Economic Journal, 100, 193–9.
136. Read, J.L. et al. (1984), ‘Preferences for Health Outcomes. Comparison of Assessment Methods’, Medical Decision Making, 4, 315–29.
137. Revicki, D.A., Luce, B.R., Wechsler, J.M., Brown, R.E. and Adler, M.A. (1990), ‘Cost-Effectiveness of Clozapine for Treatment-Resistant Schizophrenic Patients’, Hospital and Community Psychiatry, 41, 870–4.
138. Rice, D.P., Kelman, S. and Miller, L.S. (1992), ‘The Economic Burden of Mental Illness’, Hospital and Community Psychiatry, 43, 1227–32.
139. Richardson, J., Hall, J., and Salkeld, G. (1989), ‘Cost Utility Analysis: The Compatibility of Measurement Techniques and the Measurement of Utility through Time’, in Smith, S.C. (ed.), Economics and Health, Proceedings of the Eleventh Australian Conference of Health Economists.
140. Ried, W. (1998), ‘QALYs versus HYEs – What’s Right and What’s Wrong. A Review of the Controversy’, Journal of Health Economics, 17, 607–25.
141. Rosser, R. and Kind, P. (1978), ‘A Scale of Valuations of States of Illness: Is there a Social Consensus?’, International Journal of Epidemiology, 7, 347–58.
142. Russell, L.B., Gold, M.R., Siegel, J.E., Daniels, N. and Weinstein, M.C. (1996), ‘The Role of Cost-Effectiveness Analysis in Health and Medicine’, Journal of the American Medical Association, 276, 1172–7.
143. Ryan, M. (1999), ‘Using Conjoint Analysis to Take Account of Patient Preferences and Go Beyond Outcomes: An Application to In Vitro Fertilization’, Social Science and Medicine, 48, 535–46.
144. Ryan, M. and Hughes, J. (1997), ‘Using Conjoint Analysis to Assess Women’s Preferences for Miscarriage Management’, Health Economics, 6, 261–73.
145. Sackette, D.L. and Torrance, G.W. (1978), ‘The Utility of Different Health States as Perceived by the General Public’, Journal of Chronic Diseases, 31, 697–704.
146. Samuelson, P.A. (1954), ‘The Pure Theory of Public Expenditure’, Review of Economics and Statistics, 36, 350–6.
147. Schimmel, V.E., Alley, C. and Heath, A.M. (1987), ‘Measuring Costs, Product Line Accounting Versus Ratio of Cost to Charges’, Journal of Health Care Finance, 13, 76–86.
148. Shwartz, M., Young, D.W. and Siegrist, R. (1995), ‘The Ratio of Costs to Charges, How Good a Basis for Estimating Costs?’, Inquiry, 32, 476–81.
149. Siegel, C., Laska, E.M. and Meisner, M. (1996), ‘Statistical Methods for Cost-Effectiveness Analysis’, Controlled Clinical Trials, 17, 387–406.
150. Siegel, J.E., Weinstein, M.C., Russell, L.B. and Gold, M.R. (1996), ‘Recommendations for Reporting Cost-Effectiveness Analyses’, Journal of the American Medical Association, 276, 1339–41.
151. Siraprapasiri, T., Sawaddiwudhipong, W. and Rojanasuphot, S. (1997), ‘Cost Benefit Analysis of Japanese Encephalitis Vaccination Program in Thailand’, The Southeast Journal of Tropical Medicine and Public Health, 28, 143–8.
152. Squire, L. and van der Tak, H. (1975), Economic Analysis of Projects, Baltimore: Johns Hopkins.
153. Starmer, C. (2000), ‘Developments in Non-Expected Utility Theory: The Hunt for a Descriptive Theory of Choice under Risk’, Journal of Economic Literature, 38, 332–82.
154. Stason, W.B. and Weinstein, M.C. (1977), ‘Allocation of Resources to Manage Hypertension’, New England Journal of Medicine, 296, 732–9.
155. Stern, S.H., Singer, L.B. and Weissman, M.M. (1995), ‘Analysis of Hospital Cost in Total Knee Arthroplasty’, Clinical Orthopaedics and Related Research, 321, 36–44.
156. Temin, P. (1983), ‘Costs and Benefits in Switching Drugs from Rx to OTC’, Journal of Health Economics, 2, 187–205.
157. Thaler, R. and Rosen, S. (1975), ‘The Value of Saving a Life: Evidence from the Labor Market’, in Terleckyj, N. (ed.), Household Production and Consumption, New York: NBER.
158. Thompson, M.S., Read, J.S. and Liang, M. (1984), ‘Feasibility of Willingness to Pay Measurement in Chronic Arthritis’, Medical Decision Making, 4, 195–215.
159. Torrance, G.W. (1976), ‘Social Preferences for Health States: An Empirical Evaluation of Three Measurement Techniques’, Socio-Economic Planning Sciences, 10, 129–36.
160. Torrance, G.W. (1986), ‘Measurement of Health State Utilities for Economic Appraisal’, Journal of Health Economics, 5, 1–30.
161. Torrance, G.W., Boyle, M.H. and Horwood, S.P. (1982), ‘Application of Multi-Attribute Utility Theory to Measure Social Preferences for Health States’, Operations Research, 30, 1043–69.
162. Torrance, G.W. and Feeny, D. (1989), ‘Utilities and Quality-Adjusted Life Years’, International Journal of Technology Assessment in Health Care, 5, 559–75.
163. Torrance, G.W., Thomas, W.H. and Sackette, D.L. (1972), ‘A Utility Maximization Model for Evaluation of Health Care Programs’, Health Services Research, 7, 118–33.
164. Tsuchiya, A. (2000), ‘QALYs and Ageism: Philosophical Theories and Age Weighting’, Health Economics, 9, 57–68.
165. Ubel, P.A., Loewenstein, G., Scanlon, D. and Kamlet, M. (1998), ‘Value Measurement in Cost-Utility Analysis: Explaining the Discrepancy between Rating Scale and Person Trade-off Elicitations’, Health Policy, 43, 33–44.
166. Vaillant, G.E. (1983), The Natural History of Alcoholism, Cambridge, Mass.: Harvard University Press.
167. Van Hout, B.A. (1998), ‘Discounting Costs and Effects: A Reconsideration’, Health Economics, 7, 581–94.
168. Viscusi, W.K. (1995), ‘Discounting Health Effects for Medical Decisions’, in Sloan, F.A. (ed.), Valuing Health Care, New York: Cambridge University Press.
169. Von Neuman, J. and Morgenstern, O. (1944), The Theory of Games and Economic Behavior, Princeton: Princeton University Press.
170. Wagstaff, A. (1991), ‘QALYs and the Equity–Efficiency Trade-off’, Journal of Health Economics, 10, 21–41.
171. Weiers, R.M. (1998), Introduction to Business Statistics (3rd edn), New York: Duxbury.
172. Weimer, C. (1987), ‘Optimal Disease Control Through Combined Use of Preventative and Curative Measures’, Journal of Development Economics, 25, 301–19.
173. Weinstein, M.C. (1980), ‘Estrogen Use in Postmenopausal Women: Costs, Risks and Benefits’, New England Journal of Medicine, 303, 308–16.
174. Weinstein, M.C. (1995), ‘From Cost-Effectiveness Ratios to Resource Allocation’, in Sloan, F.A. (ed.), Valuing Health Care, New York: Cambridge University Press.
175. Weinstein, M.C., Siegel, J.E., Gold, M.R., Kamlet, M. and Russell, L.B. (1996),‘Recommendations of the Panel on Cost-Effectiveness in Health and Medicine’, Journal of the American Medical Association, 276, 1253–8.
176. Weinstein, M.C. and Stason, W.B. (1977), ‘Foundations of Cost-Effectiveness Analysis for Health and Medical Practices’, New England Journal of Medicine, 296, 716–21.
177. Weintraub, W.S., Mauldin, P.D., Becker, E., Kosinski, A.S. and King III, S.B. (1995), ‘A Comparison of the Costs of and Quality of Life after Coronary Artery Disease’, Circulation, 92, 2831–40.
178. Weisbrod, B.A. (1961), Economics of Public Health, University of Pennsylvania Press.
179. Weisbrod, B.A. (1971), ‘Costs and Benefits of Medical Research’, Journal of Political Economy, 79, 527–44.
180. Weisbrod, B.A., Test, M.A. and Stein, L.I. (1980), ‘Alternative to Mental Hospital Treatment’, Archives of General Psychiatry, 37, 400–5.
181. White, C.C., Koplan, J.P. and Orenstein, W.A. (1985), ‘Benefits, Risks and Costs of Immunization for Measles, Mumps and Rubella’, American Journal of Public Health, 75, 739–44.
182. Wildasin, D.E. (1992), ‘The Marginal Cost of Public Funds with an Aging Population’, in Dressen, E. and van Winden, F. (eds), Fiscal Implications of an Aging Population, Berlin: Springer-Verlag.
183. Willan, A.R. and O’Brien, B.J. (1996), ‘Confidence Intervals for Cost-Effectiveness Ratios: An Application of Fieller’s Theorem’, Health Economics, 5, 297–305.
184. Williams, A. (1997), ‘Intergenerational Equity: an Exploration of the “Fair Innings” Argument’, Health Economics, 6, 117–32.
185. Williams, A. and Cookson, R. (2000), ‘Equity in Health’, in Culyer, A.J. and Newhouse, J.P. (eds), Handbook of Health Economics, Vol. 1B, Amsterdam: Elsevier.
186. World Bank (1993), World Development Report, 1993, New York: Oxford University Press.
187. Wyatt, R.J., Henter, I., Leary, M.C. and Taylor, E. (1995), ‘An Economic Evaluation of Schizophrenia—1991’, Social Psychiatry and Psychiatric Epidemiology, 30, 196–205.
188. Zarkin, G.A., Cates, S.C. and Bala, M.V. (2000), ‘Estimating the Willingness to Pay for Drug Abuse Treatment’, Journal of Substance Abuse Treatment, 18, 149–59.